Shield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru®/Accrufer®. News that the FDA has approved this drug for a broad indication opens it up to a commercial market worth over $1bn. STX has been in discussions with a number of potential partners, but its hand has been strengthened by the regulatory de-risking of Accrufer. Its USP will be that oral Accrufer is as effective as intravenous iron. The market capitalisation equates to only 4.4x in-market sales.
If you'd like to be introduced to the team at Shield Therapeutics Plc, get in touch.Request a meeting